MUC1 and breast carcinoma: Most of the strategies employing therapeutic antibodies have targeted the variable number tandem repeat (VNTR) region and altered O-glycosylation sites of cancerous MUC1, and one of them failed in the phase II clinical study because of a lack of efficacy in breast cancer; however, the use of the AS1402 antibody as a drug candidate accelerated cancer research [24].